

- [Home](#)
- [About us](#)
- [Contact us](#)
- [Advertise](#)
- [Media Kit](#)
- [Circulation](#)
- [Editorial Calendar 2017](#)
- [Electronic Issue](#)
- [Events](#)
- [PR Newswire](#)
- [Comments](#)
- [Posts](#)



- [Home](#)
- [About us](#)
- [Contact us](#)
- [Advertise](#)
- [Media Kit](#)



[Circulation](#)

- [Editorial Calendar 2017](#)
- [Electronic Issue](#)
- [Events](#)
- [PR Newswire](#)

## PR Newswire Feeds

PRNewswire  
a CISION company

# Cedrus Investments Hosted Life Sciences Luncheon in Shanghai, 13th November 2017

HONG KONG, Nov. 14, 2017 /PRNewswire/ -- [Cedrus Investments \("Cedrus"\)](#), a global boutique investment firm, hosted the second meeting of the life sciences luncheon series for this year on Monday, 13<sup>th</sup> November 2017 in Shanghai at the St. Regis Shanghai Jingan. Mr. Randy Hice, Cedrus' Chief Technical Officer and Member of the Life Sciences Advisory Board, shared with institutional investors, venture capitalists, and company executives his insights on two crucial themes in biotechnology: "New Frontiers in Immunology R&D" and "Increasing Laboratory Productivity and Meeting FDA Compliance through Software".



Mr. Hice is recognized globally as a leading authority in laboratory informatics and the most published author in the world on topics of complex laboratory automation and workflow analysis. His recent positions included the CEO of Laboratory Expertise Center, Inc. and Manager of Global Strategy at Abbott Informatics, a division of Abbott Laboratories.

The event was well received, and elicited high-level discussion in the Q&A session following Mr. Hice's speech. Investors thought that it was especially important to understand the very latest developments in the biotech industry, as well as the overseas regulatory environment in order to conform to international conventions. Those attended the luncheon included executives from Fountainvest Partners, Franklin Templeton Sealand, Qiming VC, and SAIF Partners.

Cedrus' Chief Technical Officer, Mr. Randy Hice said, "I am glad to be able to share the latest trends in immunology research and development with investors and companies, as well as providing some perspectives on how progressive scientific enterprises are utilizing the latest tools available to improve their data quality while achieving FDA compliance. The feedback from the event's participants provided us with a better understanding of the active areas of interest from Chinese life sciences investors and companies, and that understanding will no doubt facilitate future cooperation regarding cross-border transactions and investment opportunities."

[Cedrus' Chairman, Mr. Rani Jarkas](#) said, "With its particular focus on the Greater China region, Cedrus has always positioned itself as a leader in fulfilling the needs of the investment community and companies around the world. Given our global network and expertise in the life sciences industry, we can serve as the platform for both investors and companies worldwide, facilitating both inbound and outbound investments for the Chinese and other geographical markets."

About Cedrus Investments

[Cedrus Investments](#) is a global boutique investment firm that offers expertise in [private wealth management](#), [asset management](#) and [financial advisory services](#) to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit [www.cedrusinvestments.com](http://www.cedrusinvestments.com).

Media Enquiry:  
Cedrus Investments Ltd.  
Amy Sin  
+852-3519-2828  
[information@cedrusinvestments.com](mailto:information@cedrusinvestments.com)

Logo - <http://photos.prnasia.com/prnh/20150930/8521506461LOGO>

SOURCE Cedrus Investments

[Back](#) | [Next story: Standigm, an AI based Drug Discovery Company, Launched AI Drug Discovery Services Publicly at Bio-Europe 2017 in Berlin, Germany](#)